Review Volume 11, Issue 22 pp 10771—10780

Deep biomarkers of aging and longevity: from research to applications

Alex Zhavoronkov1,2,3, , Ricky Li4, , Candice Ma5, , Polina Mamoshina6, ,

  • 1 Insilico Medicine, Hong Kong Science and Technology Park, Hong Kong, China
  • 2 The Buck Institute for Research on Aging, Novato, CA 84945, USA
  • 3 The Biogerontology Research Foundation, London, UK
  • 4 Sinovation Ventures, Beijing, China
  • 5 Sinovation AI Institute, Beijing, China
  • 6 Deep Longevity, Ltd, Hong Kong Science and Technology Park, Hong Kong, China

Received: September 2, 2019       Accepted: November 8, 2019       Published: November 25, 2019
How to Cite

Copyright © 2019 Zhavoronkov et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Multiple recent advances in machine learning enabled computer systems to exceed human performance in many tasks including voice, text, and speech recognition and complex strategy games. Aging is a complex multifactorial process driven by and resulting in the many minute changes transpiring at every level of the human organism. Deep learning systems trained on the many measurable features changing in time can generalize and learn the many biological processes on the population and individual levels. The deep age predictors can help advance aging research by establishing causal relationships in non-linear systems. Deep aging clocks can be used for identification of novel therapeutic targets, evaluating the efficacy of the various interventions, data quality control, data economics, prediction of health trajectories, mortality, and many other applications. Here we present the current state of development of the deep aging clocks in the context of the pharmaceutical research and development and clinical applications.


The recent hype cycle in artificial intelligence (AI) resulted in substantial investment in machine learning and increase in available talent in almost every industry and country. This wave of increased attention to AI was fueled by the many credible advances in deep learning that allowed machines to outperform humans in multiple tasks, including image and text recognition and as well as in the strategy board game, of Go. The advantage of deep learning (DL) systems is in their ability to learn and generalize from a large number of examples [1]. DL methods rapidly propagated into the many biomedical applications, starting primarily with the imaging, text, and genomic data [2, 3]. The availability of large volumes of data and new algorithms made it possible to use deep learning to start making predictions about the activity and pharmacological properties of small molecules [4], identify mimetics of the known geroprotectors [5, 6], and discover new ones [7]. The new techniques in deep learning converging with the advances in chemoinformatics enable the creation of completely novel molecular structures with the desired properties for the protein targets of interest in record time [812]. Many efforts are underway to apply deep learning techniques to predict the outcomes of clinical trials [13, 14]. However slowly, the artificial intelligence technologies started propagating into aging and longevity research and are rapidly increasing in popularity resulting in the formation of dedicated conference sessions and entire conferences [15] and focused reviews [16].

Over many generations humans have evolved to develop from a single-cell embryo within a female organism, come out, grow with the help of other humans, reach reproductive age, reproduce, take care of the young, and gradually decline. Due to the relatively short lifespans early in the evolutionary process, the natural age of peak and optimal performance closely follows puberty and lasts approximately one generation. Considering the average age of the Olympic athlete, the age of optimal performance can be safely defined as 20–30. Human aging is a complex multifactorial process associated with and leading to the gradual decline in all body functions, productivity, psychological changes, multiple diseases and inevitably ending in death (Figure 1).

The general course of human life in the health and performance context. Preventative strategies may increase lifespan and healthspan. Potential restorative interventions reversing the many biological clocks back to the young productive healthy state may help prevent loss of function and possibly result in future performance gains.

Figure 1. The general course of human life in the health and performance context. Preventative strategies may increase lifespan and healthspan. Potential restorative interventions reversing the many biological clocks back to the young productive healthy state may help prevent loss of function and possibly result in future performance gains.

Lifestyle and behavioral modifications may help slow down the decline and keep the organism in the best possible state for its chronological age, a term commonly referred to as “healthy aging”. To understand the differences between the “healthy aging” and “unhealthy aging”, evaluate the effects of the many lifestyle choices and a variety of emerging longevity interventions, it is essential to be able to track the rate of aging and develop a comprehensive set of aging biomarkers.

The advent of the aging clocks

There are many biological features that demonstrated correlation with the chronological age such as telomere length [17, 18], racemization of amino acids in proteins [19], and others. The epigenetic age predictors were proposed in 2011 [20]. But it was not until 2012 when the first epigenetic aging clock was published by Hannum [21]. Hannum group used profiled the methylomes derived from peripheral blood samples of healthy individuals to develop the first epigenetic clock consisting of 71 CpG sites and demonstrated the root mean squared error of 4.9 years on independent data. A more precise and comprehensive multi-tissue aging clock was then published in 2013 by Steven Horvath [22] who coined the terms “DNAm clock” and “epigenetic aging clock” and rapidly gained popularity in the aging research community. Horvath used 353 CpG sites and achieved a median error of 3.6 years on the testing set. These clocks were developed using traditional machine learning approaches—notably linear regression with regularization and the use of a limited number of samples. Similar methylation aging clocks were developed for mice [23, 24].

While the epigenetic aging clocks demonstrate spectacular performance in predicting the chronological age, the epigenetic data is not as actionable for target identification or geroprotector discovery. Another abundant and actionable data type is gene expression data. The first transcriptomic aging clock developed on blood-based transcriptomic data was published by Peters et al. in 2015 [25] and extended to other tissues by Yang et al. [26].

In addition to predicting the chronological age and establish the biological relevance of the predictor, it is possible to introduce additional metrics of health status and use the dependent variable. Levine et al. introduced a notion of phenotypic are derived from clinical data [27].

Deep aging and longevity clocks

Age is a universal feature present in all biological and non-biological material objects and is one of the most abundant features present in almost every data set. While the more traditional machine learning methods were employed to develop aging clocks on multiple data types where the many markers are statistically correlated with chronological age, the advent of deep learning lead to the emergence of next-generation of deep aging and longevity clocks. The deep learning models trained on the large numbers of examples manage to capture the highly non-linear relationships between the seemingly unrelated features.

In addition, the realization that age is a universal feature present in all biological and non-biological objects triggered the interest of the artificial intelligence researchers interested in the study of causality and making the deep neural networks (DNNs) more interpretable. This leads to the convergence of aging research and deep learning [3, 16, 28, 29].

Many of the early works in deep learning for aging research stemmed from the simple thought experiments in how humans perceive age with the various sensory organs. A human can guess with reasonable accuracy the age of another human, other species, material and non-material objects using low- and high-resolution imaging data, movement patterns, even scent and touch. When these data types can be featured and used for training and test in abundant quantity, the deep neural networks should be able to learn the features contributing to age prediction and outperform human accuracy. Most humans can describe the most important features they need to predict someone’s age. For example, the number of wrinkles, grey hair, color of the teeth and many others. The deep neural networks in theory should be able to do it even better and may be used to identify the most important features and reconstruct biological pathways implicated in aging (Figure 2A).

Training the deep neural networks on multimodal longitudinal data to predict (A) age of the individual and (B) age and health status of the individual and using the feature importance and selection approaches to infer causal relationships, pathways, and targets.

Figure 2. Training the deep neural networks on multimodal longitudinal data to predict (A) age of the individual and (B) age and health status of the individual and using the feature importance and selection approaches to infer causal relationships, pathways, and targets.

This same thought experiment can be extended to disease-specific biomarkers and disease-specific target identification. A human can quickly recognize that the other person is not feeling well just by looking at the person. A trained physician can make educated guesses about the person’s health status by examining the visual appearance. Many genetic diseases manifest in the very obvious phenotypes and can already be identified using simple imaging data using the deep neural networks [30]. Training to predict age and disease at the same time (Figure 2B) may not only enable more accurate diagnosis and training on fewer disease samples but it may be possible to compare the features and pathways between the age groups, disease stages and predictors trained to predict only age.

These though experiments help generate new hypotheses in inferring causality, multi-target processes and understand the progression of diseases better. This approach also helps combine the multiple data types, understand the relationships between the data types and control the quality of the data [31] and possibly assess its biological relevance [32]. Moreover, it may be possible to use this approach to develop “disease clocks” and track the changing importance in the molecular targets in the context of age and disease. For example, the many diseases (e.g. scleroderma) may start as an autoimmune reaction and then progress into sclerosis, fibrosis and other directions and the importance of the addressable targets may change. The techniques developed to identify the most important features and establish causality using age predictors can be used to identify the most important targets in a specific stage of the disease and personalize interventions.

With the first DNN-based aging clocks published in 2016 by Zhavoronkov laboratory [33], significant progress has been made the past few years in deep learned biomarkers of human aging [28, 29]. The first DL clock was constructed using 41 blood test values of over 50,000 individuals. Making use of DNN abilities to capture nonlinear dependencies between input data and target variable, the initially proposed method was able to achieve mean absolute accuracy of 5.5 years on previously unseen 12,000 individuals. Additionally, this study demonstrated how the deep clock can be used for further interpretations of relations between aging and blood parameters. By employing feature importance analysis they identified top parameters related to age changes.

Later, Mamoshina el al. continued the work and validated the approach on several million anonymized subject records of healthy individuals from three populations: South Korean, Canadian, and Eastern European [34]. The analysis showed that DNNs trained to predict age either on Canadian or Eastern European sample sets predict South Korean samples younger than they chronologically are. Further, for each sample with information on mortality status, the authors observed that subject with slowed aging or predicted younger have a higher life expectancy. Equally, subjects predicted older hence with accelerated aging have a lower life expectancy.

Further validation showed that deep hematological clocks can also be used to evaluate the impact of lifestyle choices on aging. In this manner, Mamoshina et al. demonstrated that tobacco smokers are predicted older than they chronologically are with individuals chronologically younger 55 years predicted twice as old [35]. In addition to age prediction, the authors showed the DNNs can also predict smoking status potentially replacing the error-prone self-reporting.

The rapid development of high-throughput methods enables the advances of DL omics-based aging clocks. While transcriptional data is among the most abundant data types, a large scale transcriptomic analysis remains a challenge [36]. Nevertheless, early in 2018, the first deep transcriptomic aging clock was presented for gene expression profiles of skeletal muscle healthy individuals [37]. The best model achieved mean absolute error of 6.24 years on unseen testing samples. To explore the age-related expression changes and evaluate the potential of age predictor to select therapeutic targets, authors compared a comprehensive set of ranking methods to identify protein-coding genes related to muscle aging.

While most of the progress has been made in the development of deep molecular aging clocks, the facial aging prediction is also a promising diagnostic tool. A research lab of the computer vision company Haut. AI proposed a deep photographic aging clock, PhotoAgeClock, developed using a set of over 8,000 anonymized high-resolution eye corner images [38]. Achieving a mean absolute error 2.3 years on the previously unseen by the model testing set, this age predictor is yet the most accurate. The proposed approach also was able to identify facial areas exposing age the most, with the skin around eye being the most age-relevant area.

Most of the practical results and most impressive achievements in deep learning are in imaging [2] and medical imaging is not an exception. Imaging-based human age predictors were developed for a variety of applications and as early as the estimation of gestational age [39].

Many deep aging clocks are being developed with the practical forensic applications in mind. Forensic age predictors were developed using femoral bone mineral density [40]. Age predictors utilizing deep learning were also developed for the estimation of age of otoliths of fish [41].

Magnetic Resonance Imaging (MRI) data is commonly used to train the deep neural networks to predict the age of the patient [42]. This technique may be used for early diagnosis and staging of a variety of neurological disorders. There are early signs that this approach may work in Multiple Sclerosis (MS) [43]. Most recently an attempt was made to correlate the predicted age by MRI and chronological age in people with depression [44]. While no meaningful correlation was found, other data types may be more applicable for this task.

Physical activity data can be used to predict the person’s age. Age predictors were developed using the data collected for people walking on a sensor floor [45].

Applications of deep aging clocks in the pharmaceutical industry

Recent advances in artificial intelligence are rapidly propagating into the pharmaceutical drug discovery and drug development practices. The intersection of recent advances in AI and aging research yields many new tools and applications for the pharmaceutical industry to exploit—at every step of the research and development process, as well as in personalization, marketing, and real-world evidence. Deep aging and longevity clocks can be applied in many areas of pharmaceutical research and development starting from biological data quality control and management to age-personalized medicine, clinical trials enrollment analysis and marketing [28].

One of the obvious applications of the deep aging clocks is evaluation of the sensitivity of a given data type to diseases and interventions. Some clocks trained on a specific data type may be relevant to the health status of the individual. For example, if the patients are consistently predicted older or younger than their chronological age during a specific disease using the hematological or transcriptomic aging clocks, these clocks are relevant to that disease and may be used for predicting the onset and stage of the disease. Other aging clocks may consistently predict the patients older or younger than their chronological age in response to a drug, gene or cell therapy, or another intervention. These clocks may be deemed to be intervention-relevant (Figure 3).

Disease-relevant aging clocks and Intervention-relevant aging clocks. The disease-relevant clock may indicate the presence or onset of a specific disease (e.g. the patient consistently "looks" older to the system then the chronological age). Intervention-relevant clocks may change in response to the intervention (e.g. the patient is consistently predicted younger than the chronological age in response to intervention).

Figure 3. Disease-relevant aging clocks and Intervention-relevant aging clocks. The disease-relevant clock may indicate the presence or onset of a specific disease (e.g. the patient consistently "looks" older to the system then the chronological age). Intervention-relevant clocks may change in response to the intervention (e.g. the patient is consistently predicted younger than the chronological age in response to intervention).

Some of the deep aging clocks may be very useful for predicting response or non-response to specific interventions. Many interventions in immuno-oncology rely on the state of patients’ immune system. The deep aging clocks may be used to track the immunosenescence levels, and identify and track new interventions designed to boost the immune system in the elderly. Biological age-personalization is another major potential application of the deep aging clock. The deep aging clocks can enable a way to track response rates. In clinical trials of meta-analysis that demonstrate patients predicted to be older than their chronological age respond better to an alternative dosage or vaccination protocol, necessary additional doses of the vaccine may be sold.

Generation of synthetic data as a tool for target identification for aging

In addition to expanding the scope of aging clocks, neural networks can be used to generate synthetic data in large volumes. Generative Adversarial Networks (GANs), a popular new machine learning technique first introduced by Ian Goodfellow in 2014 [46] commonly used in drug discovery [3], enable the generation of biologically relevant synthetic data with specified conditions. For instance, breast cancer detection requires a large number of labeled mammograms to train convolutional neural network (CNN). Generally, this kind of requirement is infeasible for the collection of medicinal images especially for the mammographic tumor images. Hence, generation of synthetic data proposed a possibility to make the CNN classifier perform better [47]. Synthesizing new patient data using GANs trained on millions of samples, using only age as a generation condition, allows for massive anonymization of data while maintaining the most biologically relevant features.

As an ideal augmentation method, GANs give a comprehensive application in both medical and biological field. It also enables the identification of potential targets driving aging and disease-related processes [16]. Many diseases related to aging can be diagnosed using multiple omics data sets in different dimensions including transcriptomics data, which is usually used in targets identification process. Recently, a universal transcriptomic signature of age performed in Caenorhabditis elegans identified a handful of molecules which extend up to 30% of mean lifespan [48]. Combining the synthetic data of different age with other various data sets provides a novel approach to create an aging clock model with pathogenic or aging-related targets identified.

Multi-modal aging clocks obscure the difference between aging and disease status, essentially turning the many aging clocks into a marker of the health status of an individual. Since all living beings change over time, multi-modal aging clocks and clock ensembles trained on all accessible data types can act as a digital twin for a patient. This likeness can be moved forward and backward in time using GANs with multiple defined generation conditions including lifestyle choices and interventions. These clocks may also be embedded into field-trainable mobile devices that learn on the individual and help maintain an optimal biological age.

Aging clocks for wellness programs

Discussions about the practicability to apply analysis of aging biomarkers [49] and data-driven behavior-tracking to health insurance risk control have been prevailing in the past decade. Meanwhile, regulations have left some room for preliminary innovations. The Affordable Care Act 2010 (ACA) and HIPAA generally interdict any means of discriminative pricing of group health plans to similarly situated individuals based on health factors such as health status, medical condition, medical history and etc. Nonetheless, HIPAA and ACA allow an exception for wellness programs under certain requirements [50].

Health insurers started to reward their members for better health habits. For instance, Oscar Health started to collect movement data through wearables, and offer $1 Amazon gift card every day to its member for hitting his or her step goal, up to $240 a year. However, the relationship between movement data and health has not been clinically established, and Oscar’s attempt to control or assess health risk with wearable data fell short of expectation [51].

A similar reward approach was proposed by VitalityHealth [52]. In addition to activity tracking, VitalityHealth also introduced a concept of Vitality Age providing rewards and benefits to individuals who chronologically are over 70, but predicted younger by simple survey-based test.

While different wellness programs are gaining popularity, identifying true healthy behavior with clinically established health risk mitigation or prevention remains a challenge. More fundamentally, insurers need a rigorous overall measure of human’s health risk and aging clocks can greatly benefit and strengthen current approaches.

Deep aging and longevity clocks for preventative and therapeutic interventions in aging

Given a sufficient number of samples for training, DNN-based systems can be trained to predict age and health status on population-level multi-modal longitudinal data within specific age groups (e.g. decades 20–30, 30–40, 40–50). These DNNs can be used to identify the most important features, reconstruct the biological pathways, evaluate the state change in the pathways [7], and identify biological targets (Figure 4). This same process can be applied on the individual level by continuous retraining of the age and health status predictors on the individual's longitudinal data.

Using age predictors within specified age groups to infer causality and identify therapeutic interventions

Figure 4. Using age predictors within specified age groups to infer causality and identify therapeutic interventions

The causal targets and networks identified using this approach may be used to develop interventions for keeping the state of the network as close to the age group with optimal performance (20–30) as possible. These interventions may be used for prevention of the age-related pathological changes.

This approach of incremental age- and health-status prediction may be used to identify pathological changes transpiring during aging and identifying therapeutic interventions required to return the individual to the state resembling the optimal biological age.


The deep biomarkers of aging and longevity have a broad range of applications in research and development, medical, insurance, and many other areas. Developing comprehensive granular multi-modal aging clocks will help get a better understanding of the aging processes, establish causal relationships, and identify preventative and therapeutic interventions. One of the many promising applications of the deep aging clocks built into the generative adversarial networks is generation of synthetic biological data with age as a generation condition. The deep aging clock research is expected to increase in popularity. Recent workshops at the National Institutes of Health (NIH) [53] and at the leading industry conferences [15] highlighted the need for development of the comprehensive deep age predictors. The authors expect this trend to continue with the inevitable commercialization in the insurance and consumer wellness industries.

Conflicts of Interest

AZ and PM work for Insilico Medicine, a for-profit longevity biotechnology company developing an end-to-end target identification and drug discovery pipeline for a broad spectrum of age-related diseases. Insilico Medicine has applied for multiple patents in the area of deep aging clocks and GAN-generated small molecules. PM is the interim CEO of Deep Longevity, Inc a company providing cloud-based deep aging and longevity clocks.


  • 1. LeCun Y, Bengio Y, Hinton G. Deep learning. Nature. 2015; 521:436–44. [PubMed]
  • 2. Mamoshina P, Vieira A, Putin E, Zhavoronkov A. Applications of Deep Learning in Biomedicine. Mol Pharm. 2016; 13:1445–54. [PubMed]
  • 3. Zhavoronkov A. Artificial Intelligence for Drug Discovery, Biomarker Development, and Generation of Novel Chemistry. Mol Pharm. 2018; 15:4311–13. [PubMed]
  • 4. Aliper A, Plis S, Artemov A, Ulloa A, Mamoshina P, Zhavoronkov A. Deep Learning Applications for Predicting Pharmacological Properties of Drugs and Drug Repurposing Using Transcriptomic Data. Mol Pharm. 2016; 13:2524–30. [PubMed]
  • 5. Aliper A, Jellen L, Cortese F, Artemov A, Karpinsky-Semper D, Moskalev A, Swick AG, Zhavoronkov A. Towards natural mimetics of metformin and rapamycin. Aging (Albany NY). 2017; 9:2245–68. [PubMed]
  • 6. Aliper A, Belikov AV, Garazha A, Jellen L, Artemov A, Suntsova M, Ivanova A, Venkova L, Borisov N, Buzdin A, Mamoshina P, Putin E, Swick AG, et al. In search for geroprotectors: in silico screening and in vitro validation of signalome-level mimetics of young healthy state. Aging (Albany NY). 2016; 8:2127–52. [PubMed]
  • 7. Zhavoronkov A, Buzdin AA, Garazha AV, Borisov NM, Moskalev AA. Signaling pathway cloud regulation for in silico screening and ranking of the potential geroprotective drugs. Front Genet. 2014; 5:49. [PubMed]
  • 8. Kadurin A, Aliper A, Kazennov A, Mamoshina P, Vanhaelen Q, Khrabrov K, Zhavoronkov A. The cornucopia of meaningful leads: applying deep adversarial autoencoders for new molecule development in oncology. Oncotarget. 2017; 8:10883–90. [PubMed]
  • 9. Kadurin A, Nikolenko S, Khrabrov K, Aliper A, Zhavoronkov A. druGAN: An Advanced Generative Adversarial Autoencoder Model for de Novo Generation of New Molecules with Desired Molecular Properties in Silico. Mol Pharm. 2017; 14:3098–104. [PubMed]
  • 10. Putin E, Asadulaev A, Vanhaelen Q, Ivanenkov Y, Aladinskaya AV, Aliper A, Zhavoronkov A. Adversarial Threshold Neural Computer for Molecular de Novo Design. Mol Pharm. 2018; 15:4386–97. [PubMed]
  • 11. Putin E, Asadulaev A, Ivanenkov Y, Aladinskiy V, Sanchez-Lengeling B, Aspuru-Guzik A, Zhavoronkov A. Reinforced Adversarial Neural Computer for de Novo Molecular Design. J Chem Inf Model. 2018; 58:1194–1204. [PubMed]
  • 12. Polykovskiy D, Zhebrak A, Vetrov D, Ivanenkov Y, Aladinskiy V, Mamoshina P, Bozdaganyan M, Aliper A, Zhavoronkov A, Kadurin A. Entangled Conditional Adversarial Autoencoder for de Novo Drug Discovery. Mol Pharm. 2018; 15:4398–405. [PubMed]
  • 13. Miotto R, Li L, Kidd BA, Dudley JT. Deep Patient: An Unsupervised Representation to Predict the Future of Patients from the Electronic Health Records. Sci Rep. 2016; 6:26094. [PubMed]
  • 14. Artemov AV, Putin E, Vanhaelen Q, Aliper A, Ozerov IV, Zhavoronkov A. Integrated deep learned transcriptomic and structure-based predictor of clinical trials outcomes. bioRxiv. 2016.
  • 15. Bakula D, Aliper AM, Mamoshina P, Petr MA, Teklu A, Baur JA, Campisi J, Ewald CY, Georgievskaya A, Gladyshev VN, Kovalchuk O, Lamming DW, Luijsterburg MS, et al. Aging and drug discovery. Aging (Albany NY). 2018; 10:3079–88. [PubMed]
  • 16. Zhavoronkov A, Mamoshina P, Vanhaelen Q, Scheibye-Knudsen M, Moskalev A, Aliper A. Artificial intelligence for aging and longevity research: recent advances and perspectives. Ageing Res Rev. 2019; 49:49–66. [PubMed]
  • 17. Zhang WG, Zhu SY, Bai XJ, Zhao DL, Jian SM, Li J, Li ZX, Fu B, Cai GY, Sun XF, Chen XM. Select aging biomarkers based on telomere length and chronological age to build a biological age equation. Age (Dordr). 2014; 36:9639. [PubMed]
  • 18. Müezzinler A, Zaineddin AK, Brenner H. A systematic review of leukocyte telomere length and age in adults. Ageing Res Rev. 2013; 12:509–19. [PubMed]
  • 19. Demarchi B, Collins M. Amino Acid Racemization Dating BT - Encyclopedia of Scientific Dating Methods. In: Rink WJ, Thompson J, editors. Dordrecht: Springer Netherlands; 2013. pp. 1–22.
  • 20. Bocklandt S, Lin W, Sehl ME, Sánchez FJ, Sinsheimer JS, Horvath S, Vilain E. Epigenetic predictor of age. PLoS One. 2011; 6:e14821. [PubMed]
  • 21. Hannum G, Guinney J, Zhao L, Zhang L, Hughes G, Sadda S, Klotzle B, Bibikova M, Fan JB, Gao Y, Deconde R, Chen M, Rajapakse I, et al. Genome-wide methylation profiles reveal quantitative views of human aging rates. Mol Cell. 2013; 49:359–67. [PubMed]
  • 22. Horvath S. DNA methylation age of human tissues and cell types. Genome Biol. 2013; 14:R115. [PubMed]
  • 23. Stubbs TM, Bonder MJ, Stark AK, Krueger F, von Meyenn F, Stegle O, Reik W, and BI Ageing Clock Team. Multi-tissue DNA methylation age predictor in mouse. Genome Biol. 2017; 18:68. [PubMed]
  • 24. Petkovich DA, Podolskiy DI, Lobanov AV, Lee SG, Miller RA, Gladyshev VN. Using DNA Methylation Profiling to Evaluate Biological Age and Longevity Interventions. Cell Metab. 2017; 25:954–960.e6. [PubMed]
  • 25. Peters MJ, Joehanes R, Pilling LC, Schurmann C, Conneely KN, Powell J, Reinmaa E, Sutphin GL, Zhernakova A, Schramm K, Wilson YA, Kobes S, Tukiainen T, et al, and NABEC/UKBEC Consortium. The transcriptional landscape of age in human peripheral blood. Nat Commun. 2015; 6:8570. [PubMed]
  • 26. Yang J, Huang T, Petralia F, Long Q, Zhang B, Argmann C, Zhao Y, Mobbs CV, Schadt EE, Zhu J, Tu Z, and GTEx Consortium. Synchronized age-related gene expression changes across multiple tissues in human and the link to complex diseases. Sci Rep. 2015; 5:15145. [PubMed]
  • 27. Levine ME, Lu AT, Quach A, Chen BH, Assimes TL, Bandinelli S, Hou L, Baccarelli AA, Stewart JD, Li Y, Whitsel EA, Wilson JG, Reiner AP, et al. An epigenetic biomarker of aging for lifespan and healthspan. Aging (Albany NY). 2018; 10:573–91. [PubMed]
  • 28. Zhavoronkov A, Mamoshina P. Deep Aging Clocks: The Emergence of AI-Based Biomarkers of Aging and Longevity. Trends Pharmacol Sci. 2019; 40:546–49. [PubMed]
  • 29. Gialluisi A, Di Castelnuovo A, Donati MB, de Gaetano G, Iacoviello L, and Moli-sani Study Investigators. Machine Learning Approaches for the Estimation of Biological Aging: The Road Ahead for Population Studies. Front Med (Lausanne). 2019; 6:146. [PubMed]
  • 30. Gurovich Y, Hanani Y, Bar O, Nadav G, Fleischer N, Gelbman D, Basel-Salmon L, Krawitz PM, Kamphausen SB, Zenker M, Bird LM, Gripp KW. Identifying facial phenotypes of genetic disorders using deep learning. Nat Med. 2019; 25:60–64. [PubMed]
  • 31. Mamoshina P, Kochetov K, Putin E, Aliper A, Zhavoronkov A. Testing for batch effect through age predictors. bioRxiv. 2019.
  • 32. Zhavoronkov A, Church G. The Advent of Human Life Data Economics. Trends Mol Med. 2019; 25:566–70. [PubMed]
  • 33. Putin E, Mamoshina P, Aliper A, Korzinkin M, Moskalev A, Kolosov A, Ostrovskiy A, Cantor C, Vijg J, Zhavoronkov A. Deep biomarkers of human aging: application of deep neural networks to biomarker development. Aging (Albany NY). 2016; 8:1021–33. [PubMed]
  • 34. Mamoshina P, Kochetov K, Putin E, Cortese F, Aliper A, Lee WS, Ahn SM, Uhn L, Skjodt N, Kovalchuk O, Scheibye-Knudsen M, Zhavoronkov A. Population Specific Biomarkers of Human Aging: A Big Data Study Using South Korean, Canadian, and Eastern European Patient Populations. J Gerontol A Biol Sci Med Sci. 2018; 73:1482–90. [PubMed]
  • 35. Mamoshina P, Kochetov K, Cortese F, Kovalchuk A, Aliper A, Putin E, Scheibye-Knudsen M, Cantor CR, Skjodt NM, Kovalchuk O, Zhavoronkov A. Blood Biochemistry Analysis to Detect Smoking Status and Quantify Accelerated Aging in Smokers. Sci Rep. 2019; 9:142. [PubMed]
  • 36. Espín-Pérez A, Portier C, Chadeau-Hyam M, van Veldhoven K, Kleinjans JC, de Kok TM. Comparison of statistical methods and the use of quality control samples for batch effect correction in human transcriptome data. PLoS One. 2018; 13:e0202947–0202947. [PubMed]
  • 37. Mamoshina P, Volosnikova M, Ozerov IV, Putin E, Skibina E, Cortese F, Zhavoronkov A. Machine Learning on Human Muscle Transcriptomic Data for Biomarker Discovery and Tissue-Specific Drug Target Identification. Front Genet. 2018; 9:242. [PubMed]
  • 38. Bobrov E, Georgievskaya A, Kiselev K, Sevastopolsky A, Zhavoronkov A, Gurov S, Rudakov K, Del Pilar Bonilla Tobar M, Jaspers S, Clemann S. PhotoAgeClock: deep learning algorithms for development of non-invasive visual biomarkers of aging. Aging (Albany NY). 2018; 10:3249–59. [PubMed]
  • 39. Desai AD, Peng C, Fang L, Mukherjee D, Yeung A, Jaffe SJ, Griffin JB, Farsiu S. Open-source, machine and deep learning-based automated algorithm for gestational age estimation through smartphone lens imaging. Biomed Opt Express. 2018; 9:6038–52. [PubMed]
  • 40. Navega D, Coelho JD, Cunha E, Curate F. DXAGE: A New Method for Age at Death Estimation Based on Femoral Bone Mineral Density and Artificial Neural Networks. J Forensic Sci. 2018; 63:497–503. [PubMed]
  • 41. Moen E, Handegard NO, Allken V, Albert OT, Harbitz A, Malde K. Automatic interpretation of otoliths using deep learning. PLoS One. 2018; 13:e0204713. [PubMed]
  • 42. Sajedi H, Pardakhti N. Age Prediction Based on Brain MRI Image: A Survey. J Med Syst. 2019; 43:279. [PubMed]
  • 43. Høgestøl EA, Kaufmann T, Nygaard GO, Beyer MK, Sowa P, Nordvik JE, Kolskår K, Richard G, Andreassen OA, Harbo HF, Westlye LT. Cross-Sectional and Longitudinal MRI Brain Scans Reveal Accelerated Brain Aging in Multiple Sclerosis. Front Neurol. 2019; 10:450. [PubMed]
  • 44. Besteher B, Gaser C, Nenadić I. Machine-learning based brain age estimation in major depression showing no evidence of accelerated aging. Psychiatry Res Neuroimaging. 2019; 290:1–4. [PubMed]
  • 45. Hoffmann R, Lauterbach C, Conradt J, Steinhage A. Estimating a person’s age from walking over a sensor floor. Comput Biol Med. 2018; 95:271–76. [PubMed]
  • 46. Goodfellow IJ, Pouget-Abadie J, Mirza M, Xu B, Warde-Farley D, Ozair S, Courville A, Bengio Y. Generative Adversarial Nets. NIPS Proceedings. 2014.
  • 47. Guan S, Loew M. Breast cancer detection using synthetic mammograms from generative adversarial networks in convolutional neural networks. J Med Imaging (Bellingham). 2019; 6:031411. [PubMed]
  • 48. Tarkhov AE, Alla R, Ayyadevara S, Pyatnitskiy M, Menshikov LI, Shmookler Reis RJ, Fedichev PO. A universal transcriptomic signature of age reveals the temporal scaling of Caenorhabditis elegans aging trajectories. Sci Rep. 2019; 9:7368. [PubMed]
  • 49. Davis JK. Justice, insurance, and biomarkers of aging. Exp Gerontol. 2010; 45:814–18. [PubMed]
  • 50. U. S. Department of Labor Employee Benefits Security Administration. FAQs on HIPAA Portability and Nondiscrimination Requirements for Employers and Advisers. 2019.
  • 51. McFall L. Personalizing solidarity? The role of self-tracking in health insurance pricing. Econ Soc. 2019; 48:52–76. [PubMed]
  • 52. VitalitityHealth - Activity tracking. 2019.
  • 53. Moore JH, Raghavachari N. Speakers, Workshop. Artificial Intelligence Based Approaches to Identify Molecular Determinants of Exceptional Health and Life Span-An Interdisciplinary Workshop at the National Institute on Aging. Front Artif Intell. 2019; 2:12.